AbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer trial suggested that patients were living longer when treated with standard therapy.
NICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer from recurring, overturning a decision earlier this year
NICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review following earlier guidance that rejected the drug.